NASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $1.02 +0.02 (+2.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.59%) As of 10/9/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Pliant Therapeutics Stock (NASDAQ:PLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pliant Therapeutics alerts:Sign Up Key Stats Today's Range$0.99▼$1.0350-Day Range$0.99▼$1.1952-Week Range$0.97▼$1.95Volume288,517 shsAverage Volume383,695 shsMarket Capitalization$63.16 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases. The company uses its expertise in integrin biology to discover and develop medicines intended to address the underlying mechanisms that contribute to tissue scarring and organ dysfunction. Pliant’s leading investigational product is bexotegrast, an oral, small-molecule inhibitor designed to selectively target the alphaVbeta6 and alphaVbeta1 integrins. The therapy has been studied in conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic liver disease. The company has also developed additional preclinical and clinical programs aimed at fibrotic and related diseases. Founded in 2015, Pliant Therapeutics is headquartered in South San Francisco, California, and its activities are primarily centered on research and clinical development. The company’s leadership has included Bernard Coulie, M.D., Ph.D., as president and chief executive officer. Pliant’s therapies remain investigational and are subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Pliant Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScorePLRX MarketRank™: Pliant Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 730th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPliant Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPliant Therapeutics has a consensus price target of $3.00, representing about 194.1% upside from its current price of $1.02.Amount of Analyst CoveragePliant Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Pliant Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($1.42) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pliant Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pliant Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.51% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 15.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.45 News SentimentPliant Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pliant Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.74% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRX Stock News HeadlinesPliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Rated "Reduce" by Wall Street BrokeragesOctober 7 at 4:15 AM | americanbankingnews.comPLRX’s FORTIFY Trial: Early Oncology Bet With Upside for Immune-Oncology InvestorsOctober 2, 2026 | tipranks.comMy next big call (under $1)On the first day of October, one of the biggest banks in the world changed its mind about Bitcoin. Citigroup raised its 12-month target from $82,000 to $113,000. This year, Citi cut its Bitcoin target three separate times. $143,000. Then $112,000. Then $82,000. Now, on day one of crypto's strongest month, it's going the other way. Banks don't flip like that on a hunch. They flip when the data forces them to. And when markets heat up, one thing rises before almost anything else: trading.October 10 at 1:00 AM | Crypto 101 Media (Ad)Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 DevelopmentOctober 1, 2026 | rttnews.comPliant Therapeutics Appoints David Raben, M.D., as Chief Medical OfficerSeptember 30, 2026 | globenewswire.comPliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from S&P Global BMI IndexSeptember 21, 2026 | marketscreener.comMPliant Therapeutics consensus price target lowered 20% to $2.04September 16, 2026 | msn.comPliant Therapeutics Inc Ordinary Shares PLRXAugust 28, 2026 | morningstar.comMSee More Headlines PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $1.22 at the beginning of 2026. Since then, PLRX shares have decreased by 16.4% and is now trading at $1.02. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.02. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $135 million in an IPO on Wednesday, June 3rd 2020. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings8/11/2026Today10/10/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PLRX's financial health is in the Yellow zone, according to TradeSmith. PLRX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PLRX CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees49Year Founded2016Price Target and Rating Average Price Target for Pliant Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+194.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.34 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.17% Return on Assets-40.46% Debt Debt-to-Equity RatioN/A Current Ratio9.90 Quick Ratio9.90 Sales & Book Value Annual Sales$1.58 million Price / Sales39.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book0.35Miscellaneous Outstanding Shares61,920,000Free Float56,510,000Market Cap$63.16 million OptionableOptionable Beta1.27 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:PLRX) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredMy next big call (under $1)On the first day of October, one of the biggest banks in the world changed its mind about Bitcoin. Citigroup r...Crypto 101 Media | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
